{"product_id":"peripheral-artery-disease-isbn-9781118776094","title":"Peripheral Artery Disease","description":"\u003cp\u003e\u003cb\u003eA comprehensive, quick-reference guide to the diagnosis and management of peripheral artery disease for non-specialists\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eWith an aging population subject to an increasing number of health risks, peripheral artery disease (PAD) is on the rise throughout the world. Because of PAD's direct links to heart attack and stroke, it is critical that internists, surgeons, cardiologists, radiologists, gerontologists, GPs, and family practitioners know how to recognize it and make the best treatment recommendations for their patients. This book provides all the expert, practical information and guidance they need to do just that. \u003c\/p\u003e \u003cp\u003eEdited by two thought leaders in PAD diagnosis and treatment, and comprising chapters written by subject matter experts, \u003ci\u003ePeripheral Artery Disease, Second Edition\u003c\/i\u003e provides clinicians with guidance on how to diagnose and treat one of the most under-diagnosed conditions affecting millions of patients. This updated and revised edition of the popular guide distills the complexities of PAD into clear, actionable advice for busy medical practitioners, providing them with the information they need—when they need it.\u003c\/p\u003e \u003cul\u003e \u003cli\u003eProvides clinicians with essential information for recognizing and treating this under-diagnosed condition that affects millions of patients\u003c\/li\u003e \u003cli\u003eDistills the complexities of PAD, from diagnosis to traditional and emerging treatment options, into clear, actionable advice for clinicians\u003c\/li\u003e \u003cli\u003eCovers PAD epidemiology, office examination, imaging, laboratory evaluation, medical therapy, surgical interventions, endovascular treatments, and much more\u003c\/li\u003e \u003cli\u003eReflects the latest PAD Guidelines and Performance Measures established by leading specialty societies\u003c\/li\u003e \u003cli\u003eFeatures contributions from internists and surgeons, all recognized experts in PAD\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003e\u003ci\u003ePeripheral Artery Disease, Second Edition\u003c\/i\u003e is an important working reference for internists, cardiologists, radiologists, and surgeons, as well as fellows and residents in those fields.\u003c\/p\u003e \u003cp\u003eContributors xi\u003c\/p\u003e \u003cp\u003ePreface xiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Epidemiology of Peripheral Artery Disease 1\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eWobo Bekwelem and Alan T. Hirsch\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eDefinitions 1\u003c\/p\u003e \u003cp\u003ePAD\u003c\/p\u003e \u003cp\u003eClinical Syndromes 2\u003c\/p\u003e \u003cp\u003ePrevalence and Incidence 3\u003c\/p\u003e \u003cp\u003eAsymptomatic PAD 8\u003c\/p\u003e \u003cp\u003eClaudication 10\u003c\/p\u003e \u003cp\u003eAtypical Leg Pain 12\u003c\/p\u003e \u003cp\u003eCritical Limb Ischemia 12\u003c\/p\u003e \u003cp\u003eAcute Limb Ischemia 13\u003c\/p\u003e \u003cp\u003eRisk Factors for Development of PAD 13\u003c\/p\u003e \u003cp\u003eTobacco Use 14\u003c\/p\u003e \u003cp\u003eDiabetes Mellitus 15\u003c\/p\u003e \u003cp\u003eDyslipidemia 15\u003c\/p\u003e \u003cp\u003eHypertension 16\u003c\/p\u003e \u003cp\u003eHomocysteinemia 16\u003c\/p\u003e \u003cp\u003eC]Reactive Protein and Fibrinogen 17\u003c\/p\u003e \u003cp\u003eObesity 17\u003c\/p\u003e \u003cp\u003eOther Risk Factors 18\u003c\/p\u003e \u003cp\u003eAwareness of PAD in the Community 20\u003c\/p\u003e \u003cp\u003eProgression, Natural History, and Outcomes of PAD 20\u003c\/p\u003e \u003cp\u003eProgression 20\u003c\/p\u003e \u003cp\u003eNatural History and Outcomes 22\u003c\/p\u003e \u003cp\u003eSummary 24\u003c\/p\u003e \u003cp\u003eReferences 26\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Office Evaluation of Peripheral Artery Disease – History and Physical Examination Strategies 37\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eMaen Nusair and Robert S. Dieter\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 37\u003c\/p\u003e \u003cp\u003eIdentifying At-Risk Individuals 37\u003c\/p\u003e \u003cp\u003eRegional Symptom Analysis 38\u003c\/p\u003e \u003cp\u003eNeurologic Symptoms 38\u003c\/p\u003e \u003cp\u003eThoracic Symptoms 40\u003c\/p\u003e \u003cp\u003eAbdominal Pain 41\u003c\/p\u003e \u003cp\u003eExtremity Pain 42\u003c\/p\u003e \u003cp\u003eSkin Manifestations 44\u003c\/p\u003e \u003cp\u003ePhysical Examination 46\u003c\/p\u003e \u003cp\u003eGeneral Appearance 46\u003c\/p\u003e \u003cp\u003eHead and Neck Examination 46\u003c\/p\u003e \u003cp\u003eChest 48\u003c\/p\u003e \u003cp\u003eAbdominal Examination 48\u003c\/p\u003e \u003cp\u003eLower Extremity Examination 49\u003c\/p\u003e \u003cp\u003ePalpating for Pulses 50\u003c\/p\u003e \u003cp\u003eAuscultation 52\u003c\/p\u003e \u003cp\u003eReferences 53\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Vascular Laboratory Evaluation of Peripheral Artery Disease 57\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eThomas Rooke\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 57\u003c\/p\u003e \u003cp\u003eAnatomic 57\u003c\/p\u003e \u003cp\u003eHemodynamic 57\u003c\/p\u003e \u003cp\u003eFunctional 58\u003c\/p\u003e \u003cp\u003ePhysiological Testing 58\u003c\/p\u003e \u003cp\u003eBackground\/History 58\u003c\/p\u003e \u003cp\u003ePhysiological Invasive Testing 58\u003c\/p\u003e \u003cp\u003ePhysiological Non]Invasive Testing 58\u003c\/p\u003e \u003cp\u003eVascular Laboratory 59\u003c\/p\u003e \u003cp\u003eDoppler 59\u003c\/p\u003e \u003cp\u003eMotion Detection 59\u003c\/p\u003e \u003cp\u003eWaveform Analysis 60\u003c\/p\u003e \u003cp\u003ePlethysmography 60\u003c\/p\u003e \u003cp\u003ePVR Amplitude 61\u003c\/p\u003e \u003cp\u003ePVR Contour 62\u003c\/p\u003e \u003cp\u003eAnkle–Brachial Index (ABI) and Segmental Pressures 63\u003c\/p\u003e \u003cp\u003eTissue Perfusion 65\u003c\/p\u003e \u003cp\u003eTranscutaneous Oximetry (TcPO2) 66\u003c\/p\u003e \u003cp\u003eDuplex Scanning 67\u003c\/p\u003e \u003cp\u003eBackground\/History 67\u003c\/p\u003e \u003cp\u003eImaging (Anatomy) 67\u003c\/p\u003e \u003cp\u003eDoppler (Hemodynamic) 68\u003c\/p\u003e \u003cp\u003eVascular Laboratory Accreditation 69\u003c\/p\u003e \u003cp\u003eReferences 69\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Magnetic Resonance, Computed Tomographic, and Angiographic Imaging of Peripheral Artery Disease 73\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eThomas Le, Masahiro Horikawa and John A. Kaufman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 73\u003c\/p\u003e \u003cp\u003eComputed Tomography Angiography 73\u003c\/p\u003e \u003cp\u003eBasics 73\u003c\/p\u003e \u003cp\u003eImage Acquisition and Interpretation 74\u003c\/p\u003e \u003cp\u003eProtocol 74\u003c\/p\u003e \u003cp\u003eAdvantages 76\u003c\/p\u003e \u003cp\u003ePitfalls 76\u003c\/p\u003e \u003cp\u003eCalcification 76\u003c\/p\u003e \u003cp\u003eArtifacts 76\u003c\/p\u003e \u003cp\u003eRadiation Exposure 76\u003c\/p\u003e \u003cp\u003eContrast]Induced Nephropathy 76\u003c\/p\u003e \u003cp\u003eAnaphylaxis 77\u003c\/p\u003e \u003cp\u003eMagnetic Resonance Angiography 77\u003c\/p\u003e \u003cp\u003eBasics 77\u003c\/p\u003e \u003cp\u003eImage Acquisition and Interpretation 77\u003c\/p\u003e \u003cp\u003eProtocol 77\u003c\/p\u003e \u003cp\u003eNon]Contrast]Enhanced MRA 77\u003c\/p\u003e \u003cp\u003eContrast]Enhanced MRA (CE]MRA) 78\u003c\/p\u003e \u003cp\u003ePost]Processing and Interpretation 78\u003c\/p\u003e \u003cp\u003eAdvantages 78\u003c\/p\u003e \u003cp\u003ePitfalls 80\u003c\/p\u003e \u003cp\u003eTime 80\u003c\/p\u003e \u003cp\u003eNephrogenic Systemic Fibrosis 80\u003c\/p\u003e \u003cp\u003eBolus Timing 80\u003c\/p\u003e \u003cp\u003eArtifacts 80\u003c\/p\u003e \u003cp\u003eOther Pitfalls 80\u003c\/p\u003e \u003cp\u003eConventional Angiography 81\u003c\/p\u003e \u003cp\u003eBasics 81\u003c\/p\u003e \u003cp\u003eImage Acquisition and Interpretation 81\u003c\/p\u003e \u003cp\u003ePre]Procedure Patient Care 81\u003c\/p\u003e \u003cp\u003eProtocol 81\u003c\/p\u003e \u003cp\u003eAdvantages 82\u003c\/p\u003e \u003cp\u003ePitfalls 82\u003c\/p\u003e \u003cp\u003eContrast]Induced Nephropathy and Anaphylaxis 82\u003c\/p\u003e \u003cp\u003eArtifacts 84\u003c\/p\u003e \u003cp\u003eOther Disadvantages 84\u003c\/p\u003e \u003cp\u003eIntravascular Ultrasonography 84\u003c\/p\u003e \u003cp\u003eBasics 84\u003c\/p\u003e \u003cp\u003eAdvantages 85\u003c\/p\u003e \u003cp\u003ePitfalls 85\u003c\/p\u003e \u003cp\u003eResults 85\u003c\/p\u003e \u003cp\u003eAortoiliac 85\u003c\/p\u003e \u003cp\u003eCTA 85\u003c\/p\u003e \u003cp\u003eMRA 86\u003c\/p\u003e \u003cp\u003eRunoff 86\u003c\/p\u003e \u003cp\u003eCTA 86\u003c\/p\u003e \u003cp\u003eMRA 86\u003c\/p\u003e \u003cp\u003ePedal 87\u003c\/p\u003e \u003cp\u003eCTA 87\u003c\/p\u003e \u003cp\u003eMRA 87\u003c\/p\u003e \u003cp\u003eConclusion 87\u003c\/p\u003e \u003cp\u003eReferences 87\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Non-atherosclerotic Peripheral Artery Disease 91\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eMitchell D. Weinberg and Ido Weinberg\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction – Presentation of Peripheral Artery Disease 91\u003c\/p\u003e \u003cp\u003eWhen Should Non-atherosclerotic Causes of PAD Be Suspected? 92\u003c\/p\u003e \u003cp\u003eEntities that Make up Non-atherosclerotic PAD 94\u003c\/p\u003e \u003cp\u003ePopliteal Artery Entrapment Syndrome 94\u003c\/p\u003e \u003cp\u003eExternal Iliac Artery Endofibrosis 98\u003c\/p\u003e \u003cp\u003eFibromuscular Dysplasia 99\u003c\/p\u003e \u003cp\u003eCystic Adventitial Disease 100\u003c\/p\u003e \u003cp\u003eVasculitis 101\u003c\/p\u003e \u003cp\u003eIdiopathic Mid]aortic Syndrome 102\u003c\/p\u003e \u003cp\u003eArterial Manifestations of Pseudoxanthoma Elasticum 102\u003c\/p\u003e \u003cp\u003eChronic Exertional Compartment Syndrome 103\u003c\/p\u003e \u003cp\u003eMusculoskeletal Pathology 103\u003c\/p\u003e \u003cp\u003eDiagnostic Evaluation of Patients with Leg Pain with Exertion 104\u003c\/p\u003e \u003cp\u003eTreatment Considerations 105\u003c\/p\u003e \u003cp\u003eConclusions 105\u003c\/p\u003e \u003cp\u003eReferences 105\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Medical Therapy of Peripheral Artery Disease 111\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eLee Joseph and Esther S. H. Kim\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 111\u003c\/p\u003e \u003cp\u003eAtherosclerotic Risk Factor Management 111\u003c\/p\u003e \u003cp\u003eHypertension 112\u003c\/p\u003e \u003cp\u003eDiabetes Mellitus 113\u003c\/p\u003e \u003cp\u003eHyperlipidemia 114\u003c\/p\u003e \u003cp\u003eTobacco Cessation 114\u003c\/p\u003e \u003cp\u003eAntiplatelet Agents 116\u003c\/p\u003e \u003cp\u003eManagement of Claudication 117\u003c\/p\u003e \u003cp\u003eClaudication Pharmacotherapy 118\u003c\/p\u003e \u003cp\u003eCilostazol 118\u003c\/p\u003e \u003cp\u003eExercise Therapy 118\u003c\/p\u003e \u003cp\u003eClaudication Management Strategies: A Comparison 119\u003c\/p\u003e \u003cp\u003eLower Extremity Wound Care 120\u003c\/p\u003e \u003cp\u003eSummary 121\u003c\/p\u003e \u003cp\u003eReferences 121\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Endovascular Treatment of Peripheral Artery Disease 129\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eVikram Prasanna, Jay Giri and R. Kevin Rogers\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 129\u003c\/p\u003e \u003cp\u003eClinical Background 129\u003c\/p\u003e \u003cp\u003eIntermittent Claudication 129\u003c\/p\u003e \u003cp\u003eCritical Limb Ischemia 131\u003c\/p\u003e \u003cp\u003eLimb Prognosis\/Overall Survival 131\u003c\/p\u003e \u003cp\u003eTypical Anatomy in Patients with CLI 131\u003c\/p\u003e \u003cp\u003ePatency Issues 131\u003c\/p\u003e \u003cp\u003eIndications for Endovascular Therapy for CLI 131\u003c\/p\u003e \u003cp\u003eBackground for Endovascular Therapy 132\u003c\/p\u003e \u003cp\u003eAnatomy 132\u003c\/p\u003e \u003cp\u003eTechnical Background 136\u003c\/p\u003e \u003cp\u003ePreprocedural Imaging 136\u003c\/p\u003e \u003cp\u003eAccess 138\u003c\/p\u003e \u003cp\u003eAnticoagulation 139\u003c\/p\u003e \u003cp\u003eAntiplatelet Management 141\u003c\/p\u003e \u003cp\u003eRadiation 143\u003c\/p\u003e \u003cp\u003eChronic Total Occlusions 143\u003c\/p\u003e \u003cp\u003eClinical Evidence for Peripheral Intervention 145\u003c\/p\u003e \u003cp\u003eAorto]Iliac Interventions 145\u003c\/p\u003e \u003cp\u003eAngioplasty vs. Stent 146\u003c\/p\u003e \u003cp\u003ePolytetrafluoroethylene (PTFE)]Covered versus Bare Metal Balloon]Expandable Stents 147\u003c\/p\u003e \u003cp\u003eFemoropopliteal Interventions 147\u003c\/p\u003e \u003cp\u003eAngioplasty versus Stenting 149\u003c\/p\u003e \u003cp\u003eDrug]Eluting Stents in Femoropopliteal Arteries 149\u003c\/p\u003e \u003cp\u003eDrug]Coated Balloon (DCB) Therapy in Femoropopliteal Disease 150\u003c\/p\u003e \u003cp\u003eCovered Stents in Femoropopliteal Disease 151\u003c\/p\u003e \u003cp\u003eAtherectomy 152\u003c\/p\u003e \u003cp\u003eSpecialty Balloons 153\u003c\/p\u003e \u003cp\u003eTibioperoneal and Pedal Interventions 153\u003c\/p\u003e \u003cp\u003ePost-procedural Care 155\u003c\/p\u003e \u003cp\u003eConclusion 155\u003c\/p\u003e \u003cp\u003eReferences 156\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Surgical Management of Peripheral Artery Disease 163\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJulia Glaser and Scott M. Damrauer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eWhen to Refer Patients with Claudication 163\u003c\/p\u003e \u003cp\u003eWhen to Refer Patients with CLI 164\u003c\/p\u003e \u003cp\u003eRevascularization Options and Results 166\u003c\/p\u003e \u003cp\u003eIliac Revascularizations 166\u003c\/p\u003e \u003cp\u003eFemoropopliteal Disease 169\u003c\/p\u003e \u003cp\u003eTibioperoneal Disease 171\u003c\/p\u003e \u003cp\u003eComplications of Revascularization 173\u003c\/p\u003e \u003cp\u003ePreoperative Evaluation and Management 175\u003c\/p\u003e \u003cp\u003eConclusion 175\u003c\/p\u003e \u003cp\u003eReferences 176\u003c\/p\u003e \u003cp\u003eIndex 179\u003c\/p\u003e   \u003cp\u003e\u003cb\u003e Emile R. Mohler, MD, MSVM, FACC, FAHA\u003c\/b\u003e is Director of Vascular Medicine for the University of Pennsylvania Health System, and Professor of Medicine for the Perelman School of Medicine at the University of Pennsylvania, Philadelphia Pennsylvania, USA   \u003c\/p\u003e\u003cp\u003e\u003cb\u003e Michael R. Jaff, DO, FACP, FACC, FAHA, MSVM\u003c\/b\u003e is Professor of Medicine, Harvard Medical School and President of Newton-Wellesley Hospital in Newton, Massachusetts, USA.    \u003c\/p\u003e\u003cp\u003e\u003cb\u003eA comprehensive, quick-reference guide to the diagnosis and management of peripheral artery disease for non-specialists \u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eWith an aging population subject to an increasing number of health risks, peripheral artery disease (PAD) is on the rise throughout the world. Because of PAD's direct links to heart attack and stroke, it is critical that internists, surgeons, cardiologists, radiologists, gerontologists, GPs, and family practitioners know how to recognize it and make the best treatment recommendations for their patients. This book provides all the expert, practical information and guidance they need to do just that.\u003c\/p\u003e \u003cp\u003eEdited by two thought leaders in PAD diagnosis and treatment, and comprising chapters written by subject matter experts, \u003ci\u003ePeripheral Artery Disease, Second Edition\u003c\/i\u003e provides clinicians with guidance on how to diagnose and treat one of the most under-diagnosed conditions affecting millions of patients. This updated and revised edition of the popular guide distills the complexities of PAD into clear, actionable advice for busy medical practitioners, providing them with the information they need—when they need it.\u003c\/p\u003e \u003cul\u003e \u003cli\u003eProvides clinicians with essential information for recognizing and treating this under-diagnosed condition that affects millions of patients\u003c\/li\u003e \u003cli\u003eDistills the complexities of PAD, from diagnosis to traditional and emerging treatment options, into clear, actionable advice for clinicians\u003c\/li\u003e \u003cli\u003eCovers PAD epidemiology, office examination, imaging, laboratory evaluation, medical therapy, surgical interventions, endovascular treatments, and much more\u003c\/li\u003e \u003cli\u003eReflects the latest PAD Guidelines and Performance Measures established by leading specialty societies\u003c\/li\u003e \u003cli\u003eFeatures contributions from internists and surgeons, all recognized experts in PAD\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003e \u003c\/p\u003e \u003cp\u003e\u003ci\u003ePeripheral Artery Disease, Second Edition\u003c\/i\u003e is an important working reference for internists, cardiologists, radiologists, and surgeons, as well as fellows and residents in those fields.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989766324453,"sku":"NP9781118776094","price":111.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781118776094.jpg?v=1761785398","url":"https:\/\/k12savings.com\/es\/products\/peripheral-artery-disease-isbn-9781118776094","provider":"K12savings","version":"1.0","type":"link"}